Evaluation of Bruton’s Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL)
Using a model-based approach showed that reducing the ibrutinib dosing regimen to 280 mg QD or even 140 mg in case of adverse events could maintain BTK inhibition over the entire dosing interval.
Authors
- Srimathi S. Srinivasan (ORCID: https://orcid.org/0000-0001-7202-9425)
- Juan José Pérez Ruixo (ORCID: https://orcid.org/0000-0001-9890-745X)
- S.R. Desphande
- Aziz Ouerdani
- Emma A. Elliott Smith (ORCID: https://orcid.org/0000-0002-3221-0737)
- Belén Valenzuela (ORCID: https://orcid.org/0000-0002-2317-5028)
- Nahor Haddish‐Berhane (ORCID: https://orcid.org/0009-0008-3071-8255)
- Nicoline Treijtel
Institutions
- Johnson & Johnson (United States) (US)
- Springhouse (US)
- Johnson & Johnson (United Kingdom) (GB)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1007/s00280-025-04753-0
- Citations
- 6
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 9.75
Funders
- Janssen Research and Development